WINT vs. APRE, CSCI, ENTO, EVOK, BMRA, SNPX, PRTG, CYCN, OBSV, and KZIA
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Aprea Therapeutics (APRE), COSCIENS Biopharma (CSCI), Entero Therapeutics (ENTO), Evoke Pharma (EVOK), Biomerica (BMRA), Synaptogenix (SNPX), Portage Biotech (PRTG), Cyclerion Therapeutics (CYCN), ObsEva (OBSV), and Novogen (KZIA). These companies are all part of the "pharmaceutical products" industry.
Windtree Therapeutics vs. Its Competitors
Aprea Therapeutics (NASDAQ:APRE) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.
Windtree Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,645.01%. Aprea Therapeutics' return on equity of -78.90% beat Windtree Therapeutics' return on equity.
Aprea Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 13.6% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Aprea Therapeutics had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Aprea Therapeutics and 0 mentions for Windtree Therapeutics. Aprea Therapeutics' average media sentiment score of 1.89 beat Windtree Therapeutics' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.
Aprea Therapeutics presently has a consensus target price of $15.50, indicating a potential upside of 926.49%. Windtree Therapeutics has a consensus target price of $350.00, indicating a potential upside of 519,959.44%. Given Windtree Therapeutics' higher possible upside, analysts clearly believe Windtree Therapeutics is more favorable than Aprea Therapeutics.
Windtree Therapeutics has lower revenue, but higher earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aprea Therapeutics beats Windtree Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:WINT) was last updated on 9/29/2025 by MarketBeat.com Staff
